Journal of Inherited Metabolic Disease

, Volume 37, Issue 4, pp 577–585 | Cite as

Defects of thiamine transport and metabolism

ICIEM Symposium 2013

Abstract

Thiamine, in the form of thiamine pyrophosphate, is a cofactor for a number of enzymes which play important roles in energy metabolism. Although dietary thiamine deficiency states have long been recognised, it is only relatively recently that inherited defects in thiamine uptake, activation and the attachment of the active cofactor to target enzymes have been described, and the underlying genetic defects identified. Thiamine is transported into cells by two carriers, THTR1 and THTR2, and deficiency of these results in thiamine-responsive megaloblastic anaemia and biotin-responsive basal ganglia disease respectively. Defective synthesis of thiamine pyrophosphate has been found in a small number of patients with episodic ataxia, delayed development and dystonia, while impaired transport of thiamine pyrophosphate into the mitochondrion is associated with Amish lethal microcephaly in most cases. In addition to defects in thiamine uptake and metabolism, patients with pyruvate dehydrogenase deficiency and maple syrup urine disease have been described who have a significant clinical and/or biochemical response to thiamine supplementation. In these patients, an intrinsic structural defect in the target enzymes reduces binding of the cofactor and this can be overcome at high concentrations. In most cases, the clinical and biochemical abnormalities in these conditions are relatively non-specific, and the range of recognised presentations is increasing rapidly at present as new patients are identified, often by genome sequencing. These conditions highlight the value of a trial of thiamine supplementation in patients whose clinical presentation falls within the spectrum of documented cases.

References

  1. Alfadhel M, Almuntashri M, Jadah RH et al (2013) Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases. Orphanet J Rare Dis 8:83PubMedCentralPubMedCrossRefGoogle Scholar
  2. Bachmann-Gagescu R, Merritt JL, 2nd, Hahn SH (2009) A cognitively normal PDH-deficient 18-year-old man carrying the R263G mutation in the PDHA1 gene. J Inherit Metab Dis 32 Suppl 1 doi: 10.1007/s10545-009-1101-4
  3. Bazarbachi A, Muakkit S, Ayas M, Taher A, Salem Z, Solh H, Haidar JH (1998) Thiamine-responsive myelodysplasia. Br J Haematol 102:1098–1100PubMedCrossRefGoogle Scholar
  4. Borgna-Pignatti C, Azzalli M, Pedretti S (2009) Thiamine-responsive megaloblastic anemia syndrome: long term follow-up. J Pediatr 155:295–297PubMedCrossRefGoogle Scholar
  5. Boros LG, Steinkamp MP, Fleming JC, Lee WN, Cascante M, Neufeld EJ (2003) Defective RNA ribose synthesis in fibroblasts from patients with thiamine-responsive megaloblastic anemia (TRMA). Blood 102:3556–3561PubMedCrossRefGoogle Scholar
  6. Boulware MJ, Subramanian VS, Said HM, Marchant JS (2003) Polarized expression of members of the solute carrier SLC19A gene family of water-soluble multivitamin transporters: implications for physiological function. Biochem J 376:43–48PubMedCentralPubMedCrossRefGoogle Scholar
  7. Casteels M, Sniekers M, Fraccascia P, Mannaerts GP, Van Veldhoven PP (2007) The role of 2-hydroxyacyl-CoA lyase, a thiamin pyrophosphate-dependent enzyme, in the peroxisomal metabolism of 3-methyl-branched fatty acids and 2-hydroxy straight-chain fatty acids. Biochem Soc Trans 35:876–880PubMedCrossRefGoogle Scholar
  8. Chuang JL, Wynn RM, Moss CC, Song JL, Li J, Awad N, Mandel H, Chuang DT (2004) Structural and biochemical basis for novel mutations in homozygous Israeli maple syrup urine disease patients: a proposed mechanism for the thiamin-responsive phenotype. J Biol Chem 279:17792–17800PubMedCrossRefGoogle Scholar
  9. Chuang DT, Chuang JL, Wynn RM (2006) Lessons from genetic disorders of branched-chain amino acid metabolism. J Nutr 136:243S–249SPubMedGoogle Scholar
  10. Dakshinamurti K (2005) Biotin–a regulator of gene expression. J Nutr Biochem 16:419–423PubMedCrossRefGoogle Scholar
  11. Debs R, Depienne C, Rastetter A et al (2010) Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. Arch Neurol 67:126–130Google Scholar
  12. Di Rocco M, Lamba LD, Minniti G, Caruso U, Naito E (2000) Outcome of thiamine treatment in a child with Leigh disease due to thiamine-responsive pyruvate dehydrogenase deficiency. Eur J Paediatr Neurol 4:115–117PubMedCrossRefGoogle Scholar
  13. Dolce V, Fiermonte G, Runswick MJ, Palmieri F, Walker JE (2001) The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc Natl Acad Sci U S A 98:2284–2288PubMedCentralPubMedCrossRefGoogle Scholar
  14. Fassone E, Wedatilake Y, DeVile CJ, Chong WK, Carr LJ, Rahman S (2013) Treatable Leigh-like encephalopathy presenting in adolescence. BMJ Case Rep 2013:200838PubMedCentralPubMedGoogle Scholar
  15. Ganapathy V, Smith SB, Prasad PD (2004) SLC19: the folate/thiamine transporter family. Pflugers Archiv: Eur J Physiol 447:641–646CrossRefGoogle Scholar
  16. Gerards M, Kamps R, van Oevelen J et al (2013) Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome. Brain 136:882–890PubMedCrossRefGoogle Scholar
  17. Kang J, Samuels DC (2008) The evidence that the DNC (SLC25A19) is not the mitochondrial deoxyribonucleotide carrier. Mitochondrion 8:103–108PubMedCrossRefGoogle Scholar
  18. Kevelam SH, Bugiani M, Salomons GS et al (2013) Exome sequencing reveals mutated SLC19A3 in patients with an early-infantile, lethal encephalopathy. Brain 136:1534–1543PubMedCrossRefGoogle Scholar
  19. Kono S, Miyajima H, Yoshida K, Togawa A, Shirakawa K, Suzuki H (2009) Mutations in a thiamine-transporter gene and Wernicke’s-like encephalopathy. New Engl J Med 360:1792–1794PubMedCrossRefGoogle Scholar
  20. Lee EH, Ahn MS, Hwang JS, Ryu KH, Kim SJ, Kim SH (2006) A Korean female patient with thiamine-responsive pyruvate dehydrogenase complex deficiency due to a novel point mutation (Y161C)in the PDHA1 gene. J Korean Med Sci 21:800–804PubMedCentralPubMedCrossRefGoogle Scholar
  21. Lindhurst MJ, Fiermonte G, Song S et al (2006) Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. Proc Natl Acad Sci U S A 103:15927–15932Google Scholar
  22. Lorber A, Gazit AZ, Khoury A, Schwartz Y, Mandel H (2003) Cardiac manifestations in thiamine-responsive megaloblastic anemia syndrome. Pediatr Cardiol 24:476–481PubMedCrossRefGoogle Scholar
  23. Marsac C, Benelli C, Desguerre I et al (1997) Biochemical and genetic studies of four patients with pyruvate dehydrogenase E1 alpha deficiency. Hum Genet 99:785–792PubMedCrossRefGoogle Scholar
  24. Mayr JA, Freisinger P, Schlachter K et al (2011) Thiamine pyrophosphokinase deficiency in encephalopathic children with defects in the pyruvate oxidation pathway. Am J Hum Genet 89:806–812PubMedCentralPubMedCrossRefGoogle Scholar
  25. Nabokina SM, Said HM (2012) A high-affinity and specific carrier-mediated mechanism for uptake of thiamine pyrophosphate by human colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 303:G389–G395PubMedCentralPubMedCrossRefGoogle Scholar
  26. Naito E, Ito M, Yokota I et al (2002a) Thiamine-responsive pyruvate dehydrogenase deficiency in two patients caused by a point mutation (F205L and L216F) within the thiamine pyrophosphate binding region. Biochim Biophys Acta 1588:79–84PubMedCrossRefGoogle Scholar
  27. Naito E, Ito M, Yokota I, Saijo T, Ogawa Y, Kuroda Y (2002b) Diagnosis and molecular analysis of three male patients with thiamine-responsive pyruvate dehydrogenase complex deficiency. J Neurol Sci 201:33–37PubMedCrossRefGoogle Scholar
  28. Neufeld EJ, Fleming JC, Tartaglini E, Steinkamp MP (2001) Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport. Blood Cell Mol Dis 27:135–138CrossRefGoogle Scholar
  29. Onal H, Baris S, Ozdil M et al (2009) Thiamine-responsive megaloblastic anemia: early diagnosis may be effective in preventing deafness. Turkish J Pediatr 51:301–304Google Scholar
  30. Ozand PT, Gascon GG, Al Essa M et al (1998) Biotin-responsive basal ganglia disease: a novel entity. Brain 121:1267–1279PubMedCrossRefGoogle Scholar
  31. Pastoris O, Savasta S, Foppa P, Catapano M, Dossena M (1996) Pyruvate dehydrogenase deficiency in a child responsive to thiamine treatment. Acta Paediatr 85:625–628PubMedCrossRefGoogle Scholar
  32. Perez-Duenas B, Serrano M, Rebollo M, Muchart J, Gargallo E, Dupuits C, Artuch R (2013) Reversible lactic acidosis in a newborn with thiamine transporter-2 deficiency. Pediatrics 131:e1670–e1675PubMedCrossRefGoogle Scholar
  33. Ricketts CJ, Minton JA, Samuel J, Ariyawansa I, Wales JK, Lo IF, Barrett TG (2006) Thiamine-responsive megaloblastic anaemia syndrome: long-term follow-up and mutation analysis of seven families. Acta Paediatr 95:99–104PubMedCrossRefGoogle Scholar
  34. Rindi G, Laforenza U (2000) Thiamine intestinal transport and related issues: recent aspects. Proc Soc Exp Biol Med 224:246–255PubMedCrossRefGoogle Scholar
  35. Rodriguez-Melendez R, Zempleni J (2003) Regulation of gene expression by biotin (review). J Nutr Biochem 14:680–690PubMedCrossRefGoogle Scholar
  36. Rosenberg MJ, Agarwala R, Bouffard G et al (2002) Mutant deoxynucleotide carrier is associated with congenital microcephaly. Nat Genet 32:175–179Google Scholar
  37. Scharfe C, Hauschild M, Klopstock T, Janssen AJ, Heidemann PH, Meitinger T, Jaksch M (2000) A novel mutation in the thiamine responsive megaloblastic anaemia gene SLC19A2 in a patient with deficiency of respiratory chain complex I. J Med Genet 37:669–673PubMedCentralPubMedCrossRefGoogle Scholar
  38. Sedel F, Challe G, Mayer JM, Boutron A, Fontaine B, Saudubray JM, Brivet M (2008) Thiamine responsive pyruvate dehydrogenase deficiency in an adult with peripheral neuropathy and optic neuropathy. J Neurol Neurosurg Psychiatr 79:846–847Google Scholar
  39. Shaw-Smith C, Flanagan SE, Patch AM et al (2012) Recessive SLC19A2 mutations are a cause of neonatal diabetes mellitus in thiamine-responsive megaloblastic anaemia. Pediatr Diabetes 13:314–321PubMedCrossRefGoogle Scholar
  40. Simon E, Flaschker N, Schadewaldt P, Langenbeck U, Wendel U (2006) Variant maple syrup urine disease (MSUD)–the entire spectrum. J Inherit Metab Dis 29:716–724PubMedCrossRefGoogle Scholar
  41. Siu VM, Ratko S, Prasad AN, Prasad C, Rupar CA (2010) Amish microcephaly: Long-term survival and biochemical characterization. Am J Med Genet A 152A:1747–1751PubMedCrossRefGoogle Scholar
  42. Spiegel R, Shaag A, Edvardson S et al (2009) SLC25A19 mutation as a cause of neuropathy and bilateral striatal necrosis. Ann Neurol 66:419–424Google Scholar
  43. Subramanian VS, Marchant JS, Said HM (2006) Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2. Am J Physiol Cell Physiol 291:C851–C859PubMedCrossRefGoogle Scholar
  44. Tabarki B, Al-Shafi S, Al-Shahwan S et al (2013) Biotin-responsive basal ganglia disease revisited: clinical, radiologic, and genetic findings. Neurology 80:261–267PubMedCrossRefGoogle Scholar
  45. Van Dongen S, Brown RM, Brown GK, Thorburn DR, Boneh A (2014) Diagnosis of thiamine-responsive and thiamine-non-responsive patients with pyruvate deydrogenase complex deficiency. JIMD Rep. doi:10.1007/8904_2014_293
  46. Vlasova TI, Stratton SL, Wells AM, Mock NI, Mock DM (2005) Biotin deficiency reduces expression of SLC19A3, a potential biotin transporter, in leukocytes from human blood. J Nutr 135:42–47PubMedCentralPubMedGoogle Scholar
  47. Yamada K, Miura K, Hara K et al (2010) A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations. BMC Med Genet 11:171PubMedCentralPubMedCrossRefGoogle Scholar
  48. Yang N, Han L, Gu X et al (2012) Analysis of gene mutations in Chinese patients with maple syrup urine disease. Mol Genet Metab 106:412–418PubMedCrossRefGoogle Scholar
  49. Zeng WQ, Al-Yamani E, Acierno JS Jr et al (2005) Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. Am J Hum Genet 77:16–26PubMedCentralPubMedCrossRefGoogle Scholar
  50. Zhao R, Goldman ID (2013) Folate and thiamine transporters mediated by facilitative carriers (SLC19A1-3 and SLC46A1) and folate receptors. Mol Aspects Med 34:373–385PubMedCrossRefGoogle Scholar
  51. Zhao R, Gao F, Goldman ID (2002) Reduced folate carrier transports thiamine monophosphate: an alternative route for thiamine delivery into mammalian cells. Am J Physiol Cell Physiol 282:C1512–C1517PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of BiochemistryUniversity of OxfordOxfordUK

Personalised recommendations